ASLAN Pharmaceuticals announced that it will be hosting a virtual research and development day on Thursday, March 16, 2023. The event will feature Key Opinion Leader Brett King, MD PhD who will discuss the unmet medical need and current limited treatments for patients suffering from alopecia areata, AA. ASLAN’s leadership team including Carl Firth PhD, Stephen Doyle, Alex Kaoukhov MD and other members of the senior R&D management team will then provide an update on its recently announced clinical program to investigate farudodstat, a novel, oral inhibitor of the enzyme dihydroorotate dehydrogenase, in a Phase 2 proof-of-concept trial, as a potential first-in-class treatment for AA. ASLAN plans to initiate a proof-of-concept study of farudodstat in AA in the second quarter of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASLN:
- Aslan Pharmaceuticals to advance farudodstat into Phase 2 clinical testing
- ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
- Aslan Pharmaceuticals price target lowered to $3 from $4 at Piper Sandler
- Aslan Pharmaceuticals price target lowered to $4.50 from $7 at H.C. Wainwright
- Aslan Pharmaceuticals announces $20M private placement
